Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICLL01 BOMP Study
2011-002307-14Phase 2Completed
- Sponsor
- Goelams
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Goelams. Primary endpoints: Overall response rate at 6 cycles of BOMP, Complete response rate at 6 cycles of BOMP and 1 more. Started Dec 2011; status: completed.
02
Drugs
bendamustineofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-002307-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002307-14.